Release date: 2007-08-02 British scientists research launches three new drugs for the treatment of rheumatoid arthritis. British scientists have shown that the latest three drugs will bring new hope to thousands of patients with rheumatoid arthritis in the UK, these new drugs can help many patients relieve pain To enable them to live an almost normal life. Baijiu Alcohol Gifts For Friend Kaoliang Liquor,Kaoliang Alcohol,Chinese Grain Alcohol,Chinese Sorghum Liquor Shan Dong Kao Shang wine industry Co.,Ltd , https://www.ksbaijiu.com
Rheumatoid arthritis is caused by the immune system invading the joints. Studies have shown that the newly developed MabThera, Orencia and Tocilizumab can alleviate the symptoms of rheumatoid arthritis and have a significant effect on joint pain, hardening and swelling caused by rheumatoid arthritis. All three drugs act on the immune system. MabThera acts on B cells of the immune system. During the trial, more than one third of the patients can reduce the symptoms by 50%. Orencia acts on immune system T cells, and if combined with methotrexate, 40% of patients can also reduce symptoms by 50%. Tocilizumab acts on the cytokine interleukin-6 and activates T cells. Although the drug has not yet been approved, clinical trials have shown similar effects to the other two drugs.
Studies have shown that all three drugs can alleviate the disease and alleviate the symptoms of the disease, especially when combined with the drug methotrexate used in the general treatment, the best results can be achieved. However, these three new drugs do not work for all patients. About 30% to 40% of patients have a marked improvement in their condition, but some patients have serious side effects.
Currently, two new drugs, MabThera and Orencia, have been approved in the UK, and Tocilizumab is subject to a period of clinical trials. Scientists say the new drug offers more opportunities to treat rheumatoid arthritis. Professor Joseph, the head of the research team, believes that the treatment of rheumatoid arthritis has entered a new historical period. Professor Paul, a British expert, said that these drugs are effective and different from existing drugs. According to Isa, CEO of the National Rheumatoid Arthritis Association, this means that we have more choices, especially for patients who are suffering from rheumatoid arthritis, a lifelong disease in their early 20s. More important.
Traditional treatments for rheumatoid arthritis include non-steroidal compounds, non-steroidal anti-inflammatory drugs, glucocorticoid steroids, etc., but the efficacy is very limited. ——Midi Medical Network